Review





Similar Products

86
Cell Signaling Technology Inc phospho stat6 y641
Phospho Stat6 Y641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+phospho+stat6+y641+antibody/pm41203944-56-10-12
Average 86 stars, based on 1 article reviews
phospho stat6 y641 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc anti pstat6 y641
Anti Pstat6 Y641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+phospho+stat6+y641+antibody/Phospho-Stat6+(Tyr641)+Antibody/pmc12549784-31-0-3
Average 95 stars, based on 1 article reviews
anti pstat6 y641 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc phospho stat6 y641 rabbit mab
(A) Cohort and study design overview. We analyzed whole exome and targeted sequencing data from 114 CHL fresh frozen samples, including 103 patients treated with ABVD-based regimens. Subsequently, we developed tissue microarrays of the cohort and applied whole transcriptome sequencing of CD30+ HRS cells using Nanostring GeoMx technology as well as multiplexed analysis using imaging mass cytometry. Key findings were validated using an independent validation cohort (n=293). (B) Oncoplot showing the most recurrently mutated genes within the CHL samples in the discovery cohort, with clinical annotations. (C) Significantly amplified (red) or deleted (blue) regions across our in-house CHL cohort. (D) Pairwise (Fisher’s exact test) comparison of the incidence of mutations within thymic vs non-thymic CHL cases. The size of the point indicating the strength of association. (E) Frequency of <t>STAT6</t> mutations in CHL according to age group (YOUNG: < 45 years, OLD: 45 years or older) at diagnosis. YOUNG: < 45 years. Fisher’s exact test was used to determine the significance of differences in observed mutational frequencies. (F) Progression-free survival (PFS) according to mutation and copy number status of STAT6 in young CHL patients (age < 45). P -values were calculated using a log rank test.
Phospho Stat6 Y641 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+phospho+stat6+y641+antibody/Stat6+Rabbit+mAb/bio_rxiv__2025__03__18__643177-260-48-64
Average 93 stars, based on 1 article reviews
phospho stat6 y641 rabbit mab - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit anti phosphostat6 y641
(A) Cohort and study design overview. We analyzed whole exome and targeted sequencing data from 114 CHL fresh frozen samples, including 103 patients treated with ABVD-based regimens. Subsequently, we developed tissue microarrays of the cohort and applied whole transcriptome sequencing of CD30+ HRS cells using Nanostring GeoMx technology as well as multiplexed analysis using imaging mass cytometry. Key findings were validated using an independent validation cohort (n=293). (B) Oncoplot showing the most recurrently mutated genes within the CHL samples in the discovery cohort, with clinical annotations. (C) Significantly amplified (red) or deleted (blue) regions across our in-house CHL cohort. (D) Pairwise (Fisher’s exact test) comparison of the incidence of mutations within thymic vs non-thymic CHL cases. The size of the point indicating the strength of association. (E) Frequency of <t>STAT6</t> mutations in CHL according to age group (YOUNG: < 45 years, OLD: 45 years or older) at diagnosis. YOUNG: < 45 years. Fisher’s exact test was used to determine the significance of differences in observed mutational frequencies. (F) Progression-free survival (PFS) according to mutation and copy number status of STAT6 in young CHL patients (age < 45). P -values were calculated using a log rank test.
Rabbit Anti Phosphostat6 Y641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+phospho+stat6+y641+antibody/Phospho-Stat6+(Tyr641)+Rabbit+mAb/pm39233229-337-31-44
Average 96 stars, based on 1 article reviews
rabbit anti phosphostat6 y641 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc anti phosphostat6 y641
Impact of TRAF3 on STAT6 activation in T cells. Primary mouse CD4 T cells or HT28.11 cells were left unstimulated, stimulated through TCR–CD28, or cultured with IL-4 for the indicated number of minutes/hours. Cells were lysed, and indicated proteins were quantified by Western blotting. A , representative Western blots of phospho-STAT6 <t>Y641</t> and total STAT6. B , quantification of independent experiments, including blot shown in ( A ). Each symbol represents one biological replicate. C , representative Western blots of phospho-STAT6 Y641 and total STAT6 in primary mouse CD4 T cells stimulated with IL-4. D , quantification of three independent experiments, including the blots shown in ( C ). Each symbol represents one biological replicate. E , representative Western blots of phospho-STAT6 Y641 and total STAT6 in HT28.11 cells stimulated with IL-4. F , quantification of six independent replicates, including the blots shown in ( E ). ∗∗∗∗ p < 0.0001 by Sidak multiple comparisons test. Error bars represent SEM. IL-4, interleukin 4; STAT6, signal transducer and activator of transcription 6; TCR; T-cell receptor; TRAF3, tumor necrosis factor receptor–associated factor 3.
Anti Phosphostat6 Y641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+phospho+stat6+y641+antibody/Phospho-Stat6+(Tyr641)+Rabbit+mAb/pmc11462019-177-46-62
Average 96 stars, based on 1 article reviews
anti phosphostat6 y641 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit anti phospho stat6 y641
Impact of TRAF3 on STAT6 activation in T cells. Primary mouse CD4 T cells or HT28.11 cells were left unstimulated, stimulated through TCR–CD28, or cultured with IL-4 for the indicated number of minutes/hours. Cells were lysed, and indicated proteins were quantified by Western blotting. A , representative Western blots of phospho-STAT6 <t>Y641</t> and total STAT6. B , quantification of independent experiments, including blot shown in ( A ). Each symbol represents one biological replicate. C , representative Western blots of phospho-STAT6 Y641 and total STAT6 in primary mouse CD4 T cells stimulated with IL-4. D , quantification of three independent experiments, including the blots shown in ( C ). Each symbol represents one biological replicate. E , representative Western blots of phospho-STAT6 Y641 and total STAT6 in HT28.11 cells stimulated with IL-4. F , quantification of six independent replicates, including the blots shown in ( E ). ∗∗∗∗ p < 0.0001 by Sidak multiple comparisons test. Error bars represent SEM. IL-4, interleukin 4; STAT6, signal transducer and activator of transcription 6; TCR; T-cell receptor; TRAF3, tumor necrosis factor receptor–associated factor 3.
Rabbit Anti Phospho Stat6 Y641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+phospho+stat6+y641+antibody/Phospho-Stat6+(Tyr641)+Rabbit+mAb/pm39178293-74-36-54
Average 96 stars, based on 1 article reviews
rabbit anti phospho stat6 y641 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc pstat6 y641
Impact of TRAF3 on STAT6 activation in T cells. Primary mouse CD4 T cells or HT28.11 cells were left unstimulated, stimulated through TCR–CD28, or cultured with IL-4 for the indicated number of minutes/hours. Cells were lysed, and indicated proteins were quantified by Western blotting. A , representative Western blots of phospho-STAT6 <t>Y641</t> and total STAT6. B , quantification of independent experiments, including blot shown in ( A ). Each symbol represents one biological replicate. C , representative Western blots of phospho-STAT6 Y641 and total STAT6 in primary mouse CD4 T cells stimulated with IL-4. D , quantification of three independent experiments, including the blots shown in ( C ). Each symbol represents one biological replicate. E , representative Western blots of phospho-STAT6 Y641 and total STAT6 in HT28.11 cells stimulated with IL-4. F , quantification of six independent replicates, including the blots shown in ( E ). ∗∗∗∗ p < 0.0001 by Sidak multiple comparisons test. Error bars represent SEM. IL-4, interleukin 4; STAT6, signal transducer and activator of transcription 6; TCR; T-cell receptor; TRAF3, tumor necrosis factor receptor–associated factor 3.
Pstat6 Y641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+phospho+stat6+y641+antibody/Phospho-Stat6+(Tyr641)+Rabbit+mAb/pm38262419-282-18-19
Average 96 stars, based on 1 article reviews
pstat6 y641 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

90
Becton Dickinson anti-phospho-stat6 (epitope y641
Impact of TRAF3 on STAT6 activation in T cells. Primary mouse CD4 T cells or HT28.11 cells were left unstimulated, stimulated through TCR–CD28, or cultured with IL-4 for the indicated number of minutes/hours. Cells were lysed, and indicated proteins were quantified by Western blotting. A , representative Western blots of phospho-STAT6 <t>Y641</t> and total STAT6. B , quantification of independent experiments, including blot shown in ( A ). Each symbol represents one biological replicate. C , representative Western blots of phospho-STAT6 Y641 and total STAT6 in primary mouse CD4 T cells stimulated with IL-4. D , quantification of three independent experiments, including the blots shown in ( C ). Each symbol represents one biological replicate. E , representative Western blots of phospho-STAT6 Y641 and total STAT6 in HT28.11 cells stimulated with IL-4. F , quantification of six independent replicates, including the blots shown in ( E ). ∗∗∗∗ p < 0.0001 by Sidak multiple comparisons test. Error bars represent SEM. IL-4, interleukin 4; STAT6, signal transducer and activator of transcription 6; TCR; T-cell receptor; TRAF3, tumor necrosis factor receptor–associated factor 3.
Anti Phospho Stat6 (Epitope Y641, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+phospho+stat6+y641+antibody/anti+human+phospho+stat6/pm38396958-307-20-59
Average 90 stars, based on 1 article reviews
anti-phospho-stat6 (epitope y641 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(A) Cohort and study design overview. We analyzed whole exome and targeted sequencing data from 114 CHL fresh frozen samples, including 103 patients treated with ABVD-based regimens. Subsequently, we developed tissue microarrays of the cohort and applied whole transcriptome sequencing of CD30+ HRS cells using Nanostring GeoMx technology as well as multiplexed analysis using imaging mass cytometry. Key findings were validated using an independent validation cohort (n=293). (B) Oncoplot showing the most recurrently mutated genes within the CHL samples in the discovery cohort, with clinical annotations. (C) Significantly amplified (red) or deleted (blue) regions across our in-house CHL cohort. (D) Pairwise (Fisher’s exact test) comparison of the incidence of mutations within thymic vs non-thymic CHL cases. The size of the point indicating the strength of association. (E) Frequency of STAT6 mutations in CHL according to age group (YOUNG: < 45 years, OLD: 45 years or older) at diagnosis. YOUNG: < 45 years. Fisher’s exact test was used to determine the significance of differences in observed mutational frequencies. (F) Progression-free survival (PFS) according to mutation and copy number status of STAT6 in young CHL patients (age < 45). P -values were calculated using a log rank test.

Journal: bioRxiv

Article Title: Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma

doi: 10.1101/2025.03.18.643177

Figure Lengend Snippet: (A) Cohort and study design overview. We analyzed whole exome and targeted sequencing data from 114 CHL fresh frozen samples, including 103 patients treated with ABVD-based regimens. Subsequently, we developed tissue microarrays of the cohort and applied whole transcriptome sequencing of CD30+ HRS cells using Nanostring GeoMx technology as well as multiplexed analysis using imaging mass cytometry. Key findings were validated using an independent validation cohort (n=293). (B) Oncoplot showing the most recurrently mutated genes within the CHL samples in the discovery cohort, with clinical annotations. (C) Significantly amplified (red) or deleted (blue) regions across our in-house CHL cohort. (D) Pairwise (Fisher’s exact test) comparison of the incidence of mutations within thymic vs non-thymic CHL cases. The size of the point indicating the strength of association. (E) Frequency of STAT6 mutations in CHL according to age group (YOUNG: < 45 years, OLD: 45 years or older) at diagnosis. YOUNG: < 45 years. Fisher’s exact test was used to determine the significance of differences in observed mutational frequencies. (F) Progression-free survival (PFS) according to mutation and copy number status of STAT6 in young CHL patients (age < 45). P -values were calculated using a log rank test.

Article Snippet: Immunoblotting was performed as previously described( Alig et al ., 2023 ) using the following primary antibodies: STAT1 Rabbit mAb (D1K9Y), STAT3 Mouse mAb (124H6), STAT6 Rabbit mAb (D3H4), AKT(pan) Rabbit mAb (C67E7), Phospho-STAT1 (Y701) Rabbit mAb (58D6), Phospho-STAT3 (Y705) Rabbit mAb (D3A7), Phospho-STAT5 (Y694) Rabbit mAb (C11C5), Phospho-STAT6 (Y641) Rabbit mAb (C11A12), Phospho-AKT (S473) Rabbit mAb (193H12), GAPDH Rabbit mAb (14C10) (all from Cell Signaling Technology, dilution 1:1000), STAT5 Rabbit polyclonalAb (C-17) (dilution 1:5000), CSF2RB (IL-3/IL-5/GM-CSFRβ Mouse mAb (A-3) (dilution 1:100) (Santa Cruz Biotechnology), followed by secondary staining using anti-Mouse (dilution 1:10000; Promega, catalog no. W4021) or Rabbit IgG (H+L) HRP conjugate (dilution 1:5000; Promega, catalog no. W4011), and detected using Amersham ECL Detection Reagents (Cytiva, catalog no. RPN3004).

Techniques: Sequencing, Imaging, Mass Cytometry, Amplification, Comparison, Mutagenesis

Impact of TRAF3 on STAT6 activation in T cells. Primary mouse CD4 T cells or HT28.11 cells were left unstimulated, stimulated through TCR–CD28, or cultured with IL-4 for the indicated number of minutes/hours. Cells were lysed, and indicated proteins were quantified by Western blotting. A , representative Western blots of phospho-STAT6 Y641 and total STAT6. B , quantification of independent experiments, including blot shown in ( A ). Each symbol represents one biological replicate. C , representative Western blots of phospho-STAT6 Y641 and total STAT6 in primary mouse CD4 T cells stimulated with IL-4. D , quantification of three independent experiments, including the blots shown in ( C ). Each symbol represents one biological replicate. E , representative Western blots of phospho-STAT6 Y641 and total STAT6 in HT28.11 cells stimulated with IL-4. F , quantification of six independent replicates, including the blots shown in ( E ). ∗∗∗∗ p < 0.0001 by Sidak multiple comparisons test. Error bars represent SEM. IL-4, interleukin 4; STAT6, signal transducer and activator of transcription 6; TCR; T-cell receptor; TRAF3, tumor necrosis factor receptor–associated factor 3.

Journal: The Journal of Biological Chemistry

Article Title: TRAF3 regulates STAT6 activation and T-helper cell differentiation by modulating the phosphatase PTP1B

doi: 10.1016/j.jbc.2024.107737

Figure Lengend Snippet: Impact of TRAF3 on STAT6 activation in T cells. Primary mouse CD4 T cells or HT28.11 cells were left unstimulated, stimulated through TCR–CD28, or cultured with IL-4 for the indicated number of minutes/hours. Cells were lysed, and indicated proteins were quantified by Western blotting. A , representative Western blots of phospho-STAT6 Y641 and total STAT6. B , quantification of independent experiments, including blot shown in ( A ). Each symbol represents one biological replicate. C , representative Western blots of phospho-STAT6 Y641 and total STAT6 in primary mouse CD4 T cells stimulated with IL-4. D , quantification of three independent experiments, including the blots shown in ( C ). Each symbol represents one biological replicate. E , representative Western blots of phospho-STAT6 Y641 and total STAT6 in HT28.11 cells stimulated with IL-4. F , quantification of six independent replicates, including the blots shown in ( E ). ∗∗∗∗ p < 0.0001 by Sidak multiple comparisons test. Error bars represent SEM. IL-4, interleukin 4; STAT6, signal transducer and activator of transcription 6; TCR; T-cell receptor; TRAF3, tumor necrosis factor receptor–associated factor 3.

Article Snippet: Rabbit antibeta actin (catalog no.: 4967), rabbit anti–phospho Akt T308 (C31E5E; catalog no.: 2965), rabbit anti–phospho Akt S473 (D9E; catalog no.: 4060), rabbit anti-JAK1 (6G4; catalog no.: 3344), rabbit anti-PTP1B (catalog no.: 5311), rabbit anti–phosphoSTAT1 Y701 (58D6; catalog no.: 9167), rabbit anti-STAT1 (catalog no.: 9172), rabbit anti–phosphoSTAT6 Y641 (D8S9Y; catalog no.: 56554), and rabbit anti-STAT6 (D3H4; catalog no.: 5397) were purchased from Cell Signaling Technologies.

Techniques: Activation Assay, Cell Culture, Western Blot

Impact of TRAF3 on IL-4-mediated STAT6 activation in T cells stimulated through TCR–CD28. Primary mouse CD4 T cells or HT28.11 cells were stimulated as indicated, then lysed, and the indicated proteins were quantified by Western blotting. A , representative Western blots of phospho-STAT6 Y641 and total STAT6 in primary mouse CD4 T cells left untreated or treated with combinations of the following: TCR–CD28 (24 h), IL-4 (during last 15 min of TCR–CD28 stimulation), and an IL-4 neutralizing antibody (24 h). B , quantification of four biological replicates, including the blots in ( A ). C , representative Western blots of phospho-STAT6 Y641 and total STAT6 in HT28.11 cells left untreated or treated with the indicated combinations of the following: TCR–CD28, 2 h; IL-4, 15 min. D , quantification of six independent replicates, including the blots in ( C ). E , STAT6 activation ratio (detailed in text) from six independent replicates, including the blots in ( C ). ∗ p < 0.05, ∗∗ p < 0.001 by Fisher multiple comparisons test ( B and D ) or unpaired t test ( E ). Error bars represent SEM. IL-4, interleukin 4; STAT6, signal transducer and activator of transcription 6; TCR; T-cell receptor; TRAF3, tumor necrosis factor receptor–associated factor 3.

Journal: The Journal of Biological Chemistry

Article Title: TRAF3 regulates STAT6 activation and T-helper cell differentiation by modulating the phosphatase PTP1B

doi: 10.1016/j.jbc.2024.107737

Figure Lengend Snippet: Impact of TRAF3 on IL-4-mediated STAT6 activation in T cells stimulated through TCR–CD28. Primary mouse CD4 T cells or HT28.11 cells were stimulated as indicated, then lysed, and the indicated proteins were quantified by Western blotting. A , representative Western blots of phospho-STAT6 Y641 and total STAT6 in primary mouse CD4 T cells left untreated or treated with combinations of the following: TCR–CD28 (24 h), IL-4 (during last 15 min of TCR–CD28 stimulation), and an IL-4 neutralizing antibody (24 h). B , quantification of four biological replicates, including the blots in ( A ). C , representative Western blots of phospho-STAT6 Y641 and total STAT6 in HT28.11 cells left untreated or treated with the indicated combinations of the following: TCR–CD28, 2 h; IL-4, 15 min. D , quantification of six independent replicates, including the blots in ( C ). E , STAT6 activation ratio (detailed in text) from six independent replicates, including the blots in ( C ). ∗ p < 0.05, ∗∗ p < 0.001 by Fisher multiple comparisons test ( B and D ) or unpaired t test ( E ). Error bars represent SEM. IL-4, interleukin 4; STAT6, signal transducer and activator of transcription 6; TCR; T-cell receptor; TRAF3, tumor necrosis factor receptor–associated factor 3.

Article Snippet: Rabbit antibeta actin (catalog no.: 4967), rabbit anti–phospho Akt T308 (C31E5E; catalog no.: 2965), rabbit anti–phospho Akt S473 (D9E; catalog no.: 4060), rabbit anti-JAK1 (6G4; catalog no.: 3344), rabbit anti-PTP1B (catalog no.: 5311), rabbit anti–phosphoSTAT1 Y701 (58D6; catalog no.: 9167), rabbit anti-STAT1 (catalog no.: 9172), rabbit anti–phosphoSTAT6 Y641 (D8S9Y; catalog no.: 56554), and rabbit anti-STAT6 (D3H4; catalog no.: 5397) were purchased from Cell Signaling Technologies.

Techniques: Activation Assay, Western Blot

Role of PTP1B in TRAF3-mediated regulation of STAT6 activation. A – C , cells of the human CD4 T-cell line HT28.11 were stimulated through TCR–CD28 and/or with IL-4, then JAK1 was immunoprecipitated, and lysates were analyzed by Western blotting. A , representative Western blots of JAK1, PTP1B, and TRAF3 coimmunoprecipitating with JAK1 (“IP:JAK1,” top ) or in whole cell lysates (“input,” bottom ) from five independent replicates. B , quantification of PTP1B coimmunoprecipitating with JAK1 from four independent replicates including the blots in ( A ) ( top ). C , quantification of TRAF3 coimmunoprecipitating with JAK1 from four independent replicates including the blots in ( A ) ( top ); only WT HT28.11 samples are quantified because TRAF3 was undetectable in crTRAF3 −/− samples. D – G , cells of the human CD4 T-cell line HT28.11 were treated with the PTP1B inhibitor TCS-401 or an equal volume of dimethyl sulfoxide (DMSO) for 2 h, stimulated through TCR–CD28 and/or with IL-4, then lysed for quantification of proteins of interest by Western blotting. D , representative Western blots of phospho-STAT6 Y641 following IL-4 stimulation for the indicated number of minutes with or without TCS-401, as indicated. E , quantification of five independent replicates, including the blots shown in ( D ). F , representative Western blots of phospho-STAT6 Y641 following TCR–CD28 and/or IL-4 stimulation, ±TCS-401/DMSO, as indicated. G , quantification of four independent replicates, including the blots shown in ( F ). ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001 by Tukey multiple comparisons test. Each graphed symbol represents an individual biological replicate, and error bars represent SEM. IL-4, interleukin 4; STAT6, signal transducer and activator of transcription 6; TCR, T-cell receptor; TRAF3, tumor necrosis factor receptor–associated factor 3.

Journal: The Journal of Biological Chemistry

Article Title: TRAF3 regulates STAT6 activation and T-helper cell differentiation by modulating the phosphatase PTP1B

doi: 10.1016/j.jbc.2024.107737

Figure Lengend Snippet: Role of PTP1B in TRAF3-mediated regulation of STAT6 activation. A – C , cells of the human CD4 T-cell line HT28.11 were stimulated through TCR–CD28 and/or with IL-4, then JAK1 was immunoprecipitated, and lysates were analyzed by Western blotting. A , representative Western blots of JAK1, PTP1B, and TRAF3 coimmunoprecipitating with JAK1 (“IP:JAK1,” top ) or in whole cell lysates (“input,” bottom ) from five independent replicates. B , quantification of PTP1B coimmunoprecipitating with JAK1 from four independent replicates including the blots in ( A ) ( top ). C , quantification of TRAF3 coimmunoprecipitating with JAK1 from four independent replicates including the blots in ( A ) ( top ); only WT HT28.11 samples are quantified because TRAF3 was undetectable in crTRAF3 −/− samples. D – G , cells of the human CD4 T-cell line HT28.11 were treated with the PTP1B inhibitor TCS-401 or an equal volume of dimethyl sulfoxide (DMSO) for 2 h, stimulated through TCR–CD28 and/or with IL-4, then lysed for quantification of proteins of interest by Western blotting. D , representative Western blots of phospho-STAT6 Y641 following IL-4 stimulation for the indicated number of minutes with or without TCS-401, as indicated. E , quantification of five independent replicates, including the blots shown in ( D ). F , representative Western blots of phospho-STAT6 Y641 following TCR–CD28 and/or IL-4 stimulation, ±TCS-401/DMSO, as indicated. G , quantification of four independent replicates, including the blots shown in ( F ). ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001 by Tukey multiple comparisons test. Each graphed symbol represents an individual biological replicate, and error bars represent SEM. IL-4, interleukin 4; STAT6, signal transducer and activator of transcription 6; TCR, T-cell receptor; TRAF3, tumor necrosis factor receptor–associated factor 3.

Article Snippet: Rabbit antibeta actin (catalog no.: 4967), rabbit anti–phospho Akt T308 (C31E5E; catalog no.: 2965), rabbit anti–phospho Akt S473 (D9E; catalog no.: 4060), rabbit anti-JAK1 (6G4; catalog no.: 3344), rabbit anti-PTP1B (catalog no.: 5311), rabbit anti–phosphoSTAT1 Y701 (58D6; catalog no.: 9167), rabbit anti-STAT1 (catalog no.: 9172), rabbit anti–phosphoSTAT6 Y641 (D8S9Y; catalog no.: 56554), and rabbit anti-STAT6 (D3H4; catalog no.: 5397) were purchased from Cell Signaling Technologies.

Techniques: Activation Assay, Immunoprecipitation, Western Blot